본문 바로가기
KERD
논문KCI 등재

Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant

박우찬|민준원|이지연|유지영|이정언|김성원|유재민|박지수|임석아|박형석|정소연|김은규
대한암학회 (Korean Cancer Association)|2020.07|Cancer Research and Treatment|제52권 제3호|pp. 680-688|DOI 10.4143/crt.2019.351

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsSurvivalPrognosisBRCA1c.5339T>Cp.Leu1780Pro
주제분류의학일반

초록

Purpose Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2mutations using Korean Hereditary Breast Cancer (KOHBRA) study data. Materials and Methods The data of 54 BC patients with L1780P variant from 10 institutions were collected and the clinicopathologic characteristics of the patients were reviewed. The hereditary breast and/or ovarian cancer–related characteristics of the L1780P variant were compared to those of BC patients in the KOHBRA study. Results The median age of all patients was 38 years, and 75.9% of cases showed triple-negative breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study revealed that the L1780P patients group was more likely to have family history (FHx) of ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients with L1780P showed similar features with BRCA1 carriers and showed higher penetrance of OC than patients with other BRCA1 mutations. Conclusion L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorectomy is highly recommended for women with L1780P.

Abstract

Purpose Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2mutations using Korean Hereditary Breast Cancer (KOHBRA) study data. Materials and Methods The data of 54 BC patients with L1780P variant from 10 institutions were collected and the clinicopathologic characteristics of the patients were reviewed. The hereditary breast and/or ovarian cancer–related characteristics of the L1780P variant were compared to those of BC patients in the KOHBRA study. Results The median age of all patients was 38 years, and 75.9% of cases showed triple-negative breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study revealed that the L1780P patients group was more likely to have family history (FHx) of ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients with L1780P showed similar features with BRCA1 carriers and showed higher penetrance of OC than patients with other BRCA1 mutations. Conclusion L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorectomy is highly recommended for women with L1780P.

참고문헌 (25)

  1. Lee EH, "Effect of BRCA1", 2 mutation on short-term and long-term breast cancer survival : a systematic review and meta-analysis, 2010, pp.122, 11~25
  2. Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history : a combined analysis of 22studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
  3. Tavtigian SV, "Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group", Hum Mutat, 29, pp.1261~1264 (2008)
  4. Ryu JM, "Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea", Breast, 33, pp.109~116 (2017)
  5. 박지수, "Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls", Cancer Research and Treatment, 49(4), pp.1012~1021 (2017), 대한암학회
  6. 윤경아, "Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients", Cancer Research and Treatment, 49(3), pp.627~634 (2017), 대한암학회
  7. Choi DH, "Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients", J Clin Oncol, 22, pp.1638~1645 (2004)
  8. Jang JH, "Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer : the importance of whole-gene sequencing", J Hum Genet, 57, pp.212~215 (2012)
  9. Han SH, "Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer", Clin Genet, 70, pp.496~501 (2006)
  10. Park KS, "Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer : a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants", Genet Med, 18, pp.1250~1257 (2016)
  11. Han SA, "The Korean Hereditary Breast Cancer(KOHBRA)study : protocols and interim report", Clin Oncol(R Coll Radiol), 23, pp.434~441 (2011)
  12. Ossa CA, "Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries : state of the art and literature review", Oncologist, 21, pp.832~839 (2016)
  13. Apostolou P, "Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation", Clin Genet, 91, pp.482~487 (2017)
  14. Rebbeck TR, "Mutational spectrum in a worldwide study of 29, 700 families with BRCA1 or BRCA2 mutations", Hum Mutat, 39, pp.593~620 (2018)
  15. Ferla R, "Founder mutations in BRCA1 and BRCA2 genes", Ann Oncol, 18(Suppl 6), pp.vi93~vi98 (2007)
  16. Kauff ND, "Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families", J Med Genet, 39, pp.611~614 (2002)
  17. Choi MC, "Unclassified variants of BRCA1 and BRCA2 in Korean patients with ovarian cancer", Int J Gynecol Cancer, 28, pp.308~315 (2018)
  18. 이지현, "Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer", Journal of Breast Cancer, 20(2), pp.203~207 (2017), 한국유방암학회[DOI]
  19. 강은영, "The Korean Hereditary Breast Cancer Study: Review and Future Perspectives", Journal of Breast Cancer, 16(3), pp.245~253 (2013), 한국유방암학회
  20. Lee MS, "Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays", Cancer Res, 70, pp.4880~4890 (2010)
  21. Rowling PJ, "Toward classification of BRCA1 missense variants using a biophysical approach", J Biol Chem, 285, pp.20080~20087 (2010)
  22. So MK, "Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast", ovarian cancer using the ACMG, Breast Cancer, pp.2019, 26[DOI]
  23. Lee JS, "Reclassification of BRCA1 and BRCA2 variants of uncertain significance : a multifactorial analysis of multicentre prospective cohort", J Med Genet, 55, pp.794~802 (2018)
  24. Rebbeck TR, "Association of type and location of BRCA1and BRCA2 mutations with risk of breast and ovarian cancer", JAMA, 313, pp.1347~1361 (2015)
  25. Park JS, "Difference in risk of breast and ovarian cancer according to putative functional domain regions in Korean BRCA1", 2 mutation carriers, 2018, pp.18, 362~373

관련 논문AI추천

Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients공선영, 박보영, 양문정, 윤경아, 이병일, 이은숙대한암학회 · Cancer Research and Treatment2017 · 제49권 제3호Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls김지은, 김태일, 남은지, 박지수, 박형석, 이승태, 이정윤, 한정우대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review권병수, 김기형, 변정미, 서동수, 신경화, 이태화, 이현주, 정대훈대한암학회 · Cancer Research and Treatment2019 · 제51권 제3호Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients권원경, 김석원, 김종원, 남석진, 방윤주, 유재민, 유종한, 이세경, 이정언, 채병주대한암학회 · Cancer Research and Treatment2022 · 제54권 제3호Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test공선영, 김룡남, 노동영, 문형곤, 박보영, 박찬이, 신희철, 유태경, 윤경아, 이은숙, 이은신, 이한별, 한원식대한암학회 · Cancer Research and Treatment2020 · 제52권 제3호Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers강한성, 강혁조, 공선영, 박보람, 박보영, 박상윤, 박수진, 이시연, 이은경, 이은숙, 임명철, 정소연, 주정남, 한재홍대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호

이 간행물의 다른 논문 (29건)

Choosing Wisely: The Korean Perspective and Launch of the ‘Right Decision in Cancer Care’ Initiative김규보, 안성귀, 이경은, 윤원섭, 강정훈, 이명아, 한동석, 김주영pp. 655-660PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs박유준, 김형호, 이혜승, 안상훈, 나희영, 고지원, 곽윤진, 이근욱, 박도중pp. 661-670Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center StudyJin Hong, Weiguo Chen, Kunwei Shen, Yafen Li, Jianrong He, Xiaosong Chen, Ou Huang, Siji Zhu, Weiqi Gao, Jiahui Huang, Chihwan Goh, Lisa Andriani, Caijin Lin, Xiaochun Fei, Linling Yin, Shuning Ding, Jiayi Wu, Li Zhu, Hui Wangpp. 671-679PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant ChemotherapyBianca Lederer, Silvia Darb-Esfahani, Gunter von Minckwitz, Sibylle Loibl, Carsten Denkert, Sanxing Guopp. 689-696Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test윤경아, 공선영, 유태경, 박보영, 문형곤, 한원식, 박찬이, 신희철, 김룡남, 이한별, 이은숙, 이은신, 노동영pp. 697-713
원문 보기